{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:45Z","timestamp":1792740765475,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system (CNS) with the presence of conformation-sensitive antibodies against MOG. The spectrum of MOGAD includes monophasic\/relapsing optic neuritis, myelitis, neuromyelitis optica spectrum disorder (NMOSD) phenotype without aquaporin 4 (AQP4) antibodies, acute\/multiphasic demyelinating encephalomyelitis (ADEM\/MDEM)-like presentation, and brainstem and cerebral cortical encephalitis. There is no apparent female preponderance in MOGAD, and MOGAD can onset in all age groups (age at onset is approximately 30\u2009years on average, and approximately 30% of cases are in the pediatric age group). While prevalence and incidence data have been available for AQP4+ NMOSD globally, such data are only beginning to accumulate for MOGAD. We reviewed the currently available data from population-based MOGAD studies conducted around the world: three studies in Europe, three in Asia, and one joint study in the Americas. The prevalence of MOGAD is approximately 1.3\u20132.5\/100,000, and the annual incidence is approximately 3.4\u20134.8 per million. Among White people, the prevalence of MOGAD appears to be slightly higher than that of AQP4+ NMOSD. No obvious latitude gradient was observed in the Japanese nationwide survey. The data available so far showed no obvious racial preponderance or strong HLA associations in MOGAD. However, precedent infection was reported in approximately 20\u201340% of MOGAD cases, and this is worthy of further investigation. Co-existing autoimmune disorders are less common in MOGAD than in AQP4+ NMOSD, but NMDAR antibodies may occasionally be positive in patients with MOGAD. More population-based studies in different populations and regions are useful to further inform the epidemiology of this disease.<\/jats:p>","DOI":"10.3389\/fneur.2023.1260358","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:32:25Z","timestamp":1695004345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":116,"title":["Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide"],"prefix":"10.3389","volume":"14","author":[{"given":"Jyh Yung","family":"Hor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","volume":"92","author":"Banks","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/jnnp-2020-324818","article-title":"Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases","volume":"92","author":"Matsumoto","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1209749","DOI":"10.3389\/fneur.2023.1209749","article-title":"Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders","volume":"14","author":"Takai","year":"2023","journal-title":"Front Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/13524585231156736","article-title":"Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey","volume":"29","author":"Nakamura","year":"2023","journal-title":"Mult Scler"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ncn3.12478","article-title":"Neuromyelitis optica spectrum disorder in Asia: epidemiology and risk factors","volume":"9","author":"Hor","year":"2021","journal-title":"Neurol Clin Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/ncn3.12479","article-title":"Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore \u2013 epidemiology and evolution of an emerging subspecialty","volume":"9","author":"Tan","year":"2021","journal-title":"Neurol Clin Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/jnnp-2022-330274","article-title":"Prevalence, incidence and clinical features of neuromyelitis optica spectrum disorders in northern Japan","volume":"94","author":"Houzen","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O\u2019Connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"103884","DOI":"10.1016\/j.msard.2022.103884","article-title":"Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy","volume":"63","author":"Orlandi","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"104511","DOI":"10.1016\/j.msard.2023.104511","article-title":"The epidemiology and burden of neuromyelitis optica spectrum disorder, multiple sclerosis, and MOG antibody-associated disease in a province in Thailand: a population-based study","volume":"70","author":"Tisavipat","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref26","first-page":"160","article-title":"The epidemiology of myelin oligodendrocyte glycoprotein antibody associated disorders","volume":"25","author":"Flanagan","year":"2019","journal-title":"Mult Scler"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad122","article-title":"Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids","author":"Matsumoto","year":"2023","journal-title":"Brain"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult Scler"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"103258","DOI":"10.1016\/j.msard.2021.103258","article-title":"Neuromyelitis optica spectrum disorders: a nationwide Portuguese clinical epidemiological study","volume":"56","author":"Santos","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"104488","DOI":"10.1016\/j.msard.2022.104488","article-title":"Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in S\u00e3o Paulo, Brazil","volume":"70","author":"Silva","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.msard.2023.104787","article-title":"Clinical course, imaging, and pathological features of 45 adult and pediatric cases of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"76","author":"Boudjani","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.braindev.2021.01.008","article-title":"A nation-wide survey of Japanese pediatric MOG antibody-associated diseases","volume":"43","author":"Azumagawa","year":"2021","journal-title":"Brain and Dev"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"104141","DOI":"10.1016\/j.msard.2022.104141","article-title":"Onset of various CNS inflammatory demyelinating diseases following COVID-19 vaccinations","volume":"68","author":"Kim","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e200063","DOI":"10.1212\/NXI.0000000000200063","article-title":"Acute inflammatory disease of the central nervous system after SARS-CoV-2 vaccination","volume":"10","author":"Francis","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"525933","DOI":"10.3389\/fneur.2020.525933","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody positive patients in a multi-ethnic Canadian cohort","volume":"11","author":"Cross","year":"2021","journal-title":"Front Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1177\/1352458520933884","article-title":"Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/1352458520951046","article-title":"MOG-IgG1 and co-existence of neuronal autoantibodies","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"20552173221128170","DOI":"10.1177\/20552173221128170","article-title":"Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a systematic review","volume":"8","author":"Molazadeh","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1212\/NXI.0000000000000702","article-title":"HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population","volume":"7","author":"Bruijstens","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/acn3.51147","article-title":"Genetic factors for susceptibility to and manifestations of neuromyelitis optica","volume":"7","author":"Matsushita","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"13706","DOI":"10.1038\/s41598-020-69224-3","article-title":"Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population","volume":"10","author":"Romero-Hidalgo","year":"2020","journal-title":"Sci Rep"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41598-020-80535-3","article-title":"Neuromyelitis optica is an HLA associated disease different from multiple sclerosis: a systematic review with meta-analysis","volume":"11","author":"Alvarenga","year":"2021","journal-title":"Sci Rep"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/acn3.51378","article-title":"No strong HLA association with MOG antibody disease in the UK population","volume":"8","author":"Grant-Peters","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/jnnp-2019-322115","article-title":"Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort","volume":"91","author":"Sun","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"577937","DOI":"10.1016\/j.jneuroim.2022.577937","article-title":"Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms","volume":"372","author":"Shu","year":"2022","journal-title":"J Neuroimmunol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"577431","DOI":"10.1016\/j.jneuroim.2020.577431","article-title":"Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody","volume":"349","author":"Akaishi","year":"2020","journal-title":"J Neuroimmunol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jnnp-2020-324422","article-title":"Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany","volume":"92","author":"Liu","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"116881","DOI":"10.1016\/j.jns.2020.116881","article-title":"Seasonal distribution of attacks in aquaporin-4 antibody and myelin-oligodendrocyte antibody disease","volume":"415","author":"dos Passos","year":"2020","journal-title":"J Neurol Sci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1260358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:32:27Z","timestamp":1695004347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1260358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":52,"alternative-id":["10.3389\/fneur.2023.1260358"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1260358","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"article-number":"1260358"}}